達(dá)格列酮
|
|
- CAS號(hào):
- 141200-24-0
- 英文名:
- darglitazone
- 英文別名:
- darglitazone;2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-;5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione;oral,UCP2,corticosterone,PPAR-γ,CP86325,Darglitazone,Diabetes,CP-86325,Inhibitor,PPAR,inhibit,Peroxisome proliferator-activated receptors,CP 86325,thiazolidinedione
- 中文名:
- 達(dá)格列酮
- 中文別名:
- 達(dá)格列酮;化合物 T22708
- CBNumber:
- CB41382639
- 分子式:
- C23H20N2O4S
- 分子量:
- 420.48
- MOL File:
- 141200-24-0.mol
|
|
|
達(dá)格列酮化學(xué)性質(zhì)
-
密度:
-
1.306±0.06 g/cm3(Predicted)
-
|
-
儲(chǔ)存條件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO:20.0(Max Conc. mg/mL);47.56(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);47.56(Max Conc. mM) -
|
-
形態(tài):
-
A crystalline solid
-
|
-
酸度系數(shù)(pKa):
-
6.22±0.50(Predicted)
-
|
-
顏色:
-
White to light yellow
-
|
達(dá)格列酮性質(zhì)、用途與生產(chǎn)工藝
Darglitazone (CP-86325),一種噻唑烷二酮,是一種有效的,選擇性的和具有口服活性的 PPAR-γ 激動(dòng)劑。Darglitazone 有效控制血糖和脂質(zhì)代謝,可用于 II 型糖尿病研究。
In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ.
Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24?h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult.
Animal Model:
|
Male diabetic ob/ob mice
|
Dosage:
|
1?mg/kg
|
Administration:
|
Oral administration; daily; for 7 days
|
Result:
|
Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice.
|
達(dá)格列酮
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS編號(hào) | 包裝 | 價(jià)格 |
---|
2025/02/08 | HY-120160 | 達(dá)格列酮 Darglitazone | 141200-24-0 | 1 mg | 350元 |
2025/02/08 | HY-120160 | 達(dá)格列酮 Darglitazone | 141200-24-0 | 5 mg | 780元 |
141200-24-0, 達(dá)格列酮 相關(guān)搜索:
- 抑制劑
- 化合物 T22708
- 達(dá)格列酮
- 141200-24-0
- oral,UCP2,corticosterone,PPAR-γ,CP86325,Darglitazone,Diabetes,CP-86325,Inhibitor,PPAR,inhibit,Peroxisome proliferator-activated receptors,CP 86325,thiazolidinedione
- 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
- 2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-
- darglitazone